Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2014, Article ID 260672, 7 pages
Research Article

Cardioprotective Activity of , -Bis[5-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]carbonohydrazide Derivative against Doxorubicin Induced Cardiotoxicity in Rats

1Department of Pharmacology, Vaageswari College of Pharmacy, Rama Krishna Colony, Beside LMD Police Station, Karimnagar, Andhra Pradesh 505 481, India
2Department of Pharmaceutical Chemistry, Kakatiya Institute of Pharmaceutical Sciences, Pembarthy, Hasanparthy, Warangal 506 371, India
3Center for Pharmaceutical Sciences, IST, JNTU, Kukatpally, Hyderabad 500085, India
4Deparment of Pharmaceutics, SVS School of Pharmacy, SVS group of Institutions, Ramaram, Hanamkonda, Warangal 506 015, India
5Department of Pharmaceutical Chemistry, University College of Pharmaceutical Sciences, Kakatiya University, Warangal 506 009, India

Received 25 May 2013; Accepted 18 November 2013; Published 28 January 2014

Academic Editor: Isabel Seiquer

Copyright © 2014 Salma Tabassum et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Huang, X. Zhang, J. M. Ramil et al., “Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice,” Circulation, vol. 121, no. 5, pp. 675–683, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Fuster and B. B. Kelly, Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health, National Academies Press, 2010.
  3. K. A. Reimer and R. B. Jennings, “Myocardial ischemia, hypoxia, and infarction,” The Heart and Cardiovascular System, vol. 2, pp. 1133–1201, 1992. View at Google Scholar
  4. B. Bhrigu, D. Pathak, N. Siddiqui, M. S. Alam, and W. Ahsan, “Search for biological active isatins: a short review,” International Journal of Pharmaceutical Sciences & Drug Research, vol. 2, no. 4, pp. 229–235, 2010. View at Google Scholar
  5. S. N. Pandeya, S. Smitha, M. Jyoti, and S. K. Sridhar, “Biological activities of isatin and its derivatives,” Acta Pharmaceutica, vol. 55, no. 1, pp. 27–46, 2005. View at Google Scholar · View at Scopus
  6. P. K. Singal and N. Iliskovic, “Doxorubicin-induced cardiomyopathy,” The New England Journal of Medicine, vol. 339, no. 13, pp. 900–905, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. N. Nagi and M. A. Mansour, “Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection,” Pharmacological Research, vol. 41, no. 3, pp. 283–289, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. A. J. Bakker, B. Mirchi, J. T. Dijkstra, F. Reitsma, H. Syperda, and A. Zijlstra, “IFCC method for lactate dehydrogenase measurement in heparin plasma is unreliable,” Clinical Chemistry, vol. 49, no. 4, pp. 662–664, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Panteghini, F. Ceriotti, G. Schumann, and L. Siekmann, “Establishing a reference system in clinical enzymology,” Clinical Chemistry and Laboratory Medicine, vol. 39, no. 9, pp. 795–800, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Bucolo and H. David, “Quantitative determination of serum triglycerides by the use of enzymes,” Clinical Chemistry, vol. 19, no. 5, pp. 476–482, 1973. View at Google Scholar · View at Scopus
  11. H. Aebi, “Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984. View at Publisher · View at Google Scholar · View at Scopus
  12. H. P. Misra and I. Fridovich, “Superoxide dismutase: a photochemical augmentation assay,” Archives of Biochemistry and Biophysics, vol. 181, no. 1, pp. 308–312, 1977. View at Google Scholar · View at Scopus
  13. E. Beutler, O. Duron, and B. M. Kelly, “Improved method for the determination of blood glutathione,” The Journal of Laboratory and Clinical Medicine, vol. 61, pp. 882–888, 1963. View at Google Scholar · View at Scopus
  14. A. R. N. Reddy, J. Nagarajua, G. Rajyalaksmib, and M. Sarangapanib, “Cardioprotective effect of N-(benzo[d]oxazol-2-yl)-2-(5-bromo-2-oxoindolin-3-ylidene)hydrazinecarboxamide against doxorubicin induced cardiotoxicity in rats,” Toxicological & Environmental Chemistry, vol. 94, no. 10, pp. 2012–2018, 2012. View at Google Scholar
  15. F. S. Carvalho, A. Burgeiro, R. Garcia, A. J. Moreno, R. A. Carvalho, and P. J. Oliveira, “Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy,” Medicinal Research Reviews, vol. 34, no. 1, pp. 106–135, 2014. View at Google Scholar
  16. P. K. Singal, N. Iliskovic, T. Li, and D. Kumar, “Adriamycin cardiomyopathy: pathophysiology and prevention,” The FASEB Journal, vol. 11, no. 12, pp. 931–936, 1997. View at Google Scholar · View at Scopus
  17. A. R. Lehenbauer Ludke, A. A.-R. S. Al-Shudiefat, S. Dhingra, D. S. Jassal, and P. K. Singal, “A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity,” Canadian Journal of Physiology and Pharmacology, vol. 87, no. 10, pp. 756–763, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. R. D. Olson, J. S. MacDonald, and C. J. VanBoxtel, “Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin,” Journal of Pharmacology and Experimental Therapeutics, vol. 215, no. 2, pp. 450–454, 1980. View at Google Scholar · View at Scopus
  19. G. Chen, Y. Wang, X. Hao, S. Mu, and Q. Sun, “Simple isatin derivatives as free radical scavengers: synthesis, biological evaluation and structure-activity relationship,” Chemistry Central Journal, vol. 5, no. 1, article 37, 2011. View at Publisher · View at Google Scholar · View at Scopus